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The production of therapeutic antibodies to combat pathogens and treat diseases, such
as cancer is of great interest for the biotechnology industry. The recent development of
plant-based expression systems has demonstrated that plants are well-suited for the
production of recombinant monoclonal antibodies with defined glycosylation. Compared
to immunoglobulin G (IgG), less effort has been undertaken to express immunoglobulin
A (IgA), which is the most prevalent antibody class at mucosal sites and a promising
candidate for novel recombinant biopharmaceuticals with enhanced anti-tumor activity.
Here, we transiently expressed recombinant human IgA1 against the VP8* rotavirus
antigen in glyco-engineered XT/FT Nicotiana benthamiana plants. Mass spectrometric
analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans
with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2
domain in the IgA1 alpha chain. Analysis of the peptide carrying nine potential
O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of
plant-specific modifications including hydroxyproline formation and the attachment of
pentoses. By co-expression of enzymes required for initiation and elongation of human
O-glycosylation it was possible to generate disialylated mucin-type core 1 O-glycans on
plant-produced IgA1. Our data demonstrate that XT/FT N. benthamiana plants can
be engineered toward the production of recombinant IgA1 with defined human-type N-
and O-linked glycans.
Keywords: monomeric IgA, antibody, protein glycosylation, N-glycosylation, O-glycosylation, glyco-engineering,
recombinant glycoprotein, plant-made pharmaceuticals
INTRODUCTION
Therapeutic antibodies are an increasingly important class of recombinant biopharmaceuticals for
treatment of cancer or infectious diseases. Currently the majority of antibody-based therapeutics
on the market or in clinical trials are monoclonal and of the IgG subtype. Immunoglobulin A
(IgA) – the most prevalent antibody class at mucosal sites in the human body – is gaining attention
as therapeutic agent for treatment of infections and cancer (Bakema and van Egmond, 2011;
Abbreviations: GALNAc-T2, polypetide-N-acetylgalactosaminyltransferase 2.
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Boross et al., 2013; Reinhart and Kunert, 2015). However, the
full potential of recombinant IgAs as therapeutic antibodies is
still not fully explored, owing to the fact that robust recombinant
production is challenging and that IgAs are extensively
glycosylated proteins. IgGs contain a single N-glycosylation
site in the heavy chain Fc region, which is heterogeneously
glycosylated. Importantly, distinct IgG N-glycan structures can
aﬀect the antibody activity in therapeutic settings through the
modulation of Fc receptor binding on diﬀerent immune cells
(Jeﬀeris, 2009; Ferrara et al., 2011; Lin et al., 2015). Recent
advances in glyco-engineering in diverse expression hosts allow
the recombinant generation of IgG glycoforms for structure-
function studies and comparison of eﬃcacy (Strasser et al., 2014).
The ﬁrst glyco-engineered IgG-based monoclonal antibodies
have already been approved for therapeutic applications (Beck
and Reichert, 2012; Ratner, 2014; Goede et al., 2015).
Despite the recognized importance of N-glycosylation for
IgG function, comparatively little is known about the role of
glycosylation for the biophysical and immunological properties
of IgA as well as on the in vivo role of diﬀerent IgA glycoforms.
The two IgA isotypes (IgA1 and IgA2) carry two to ﬁve
N-glycosylation sites on the alpha chain, and the hinge region of
IgA1 is modiﬁed with several mucin-type O-glycans (Royle et al.,
2003; Deshpande et al., 2010; Huang et al., 2015) (Figure 1A).
Aberrantly O-glycosylated IgA1 is involved in pathogenesis
of IgA nephropathy in humans (Novak et al., 2012). In this
autoimmune disease the galactose-deﬁcient O-glycans in the
IgA1 hinge region are recognized by circulating autoantibodies
resulting in the formation of immune complexes, followed by
aggregation or disposition, which is a major cause of renal
failure. Moreover, the joining (J) chain in the dimeric IgA variant
contains a single N-glycan and the secretory component (SC)
in the secretory IgA (sIgA) variant is heavily N-glycosylated
(Huang et al., 2015). Hence, the generation of recombinant IgA
variants bearing homogeneous and well-deﬁned glycans is highly
challenging. Nonetheless, such glyco-engineering approaches are
imperative to study the contribution of N- and O-glycosylation
to IgA function. Furthermore, in the case of therapeutic
applications abnormal glycosylation such as galactose-deﬁcient
IgA1 O-glycans variants should be avoided to reduce the risk of
adverse side eﬀects like the formation of anti-glycan antibodies
(Suzuki et al., 2015).
Plants are considered attractive hosts for the production
of recombinant biopharmaceuticals. For example, a phase I
clinical trial of tobacco-derived HIV neutralizing antibody 2G12
has recently been completed (Ma et al., 2015). The tobacco-
related species Nicotiana benthamiana has emerged as promising
host for expression of recombinant glycoproteins with tailor-
made N- and O-glycan modiﬁcations (Strasser et al., 2014).
IgG variants with diﬀerent types of customized N-glycans have
been successfully generated in this expression platform (Strasser
et al., 2008, 2009) and the ZMAPPTM monoclonal IgG antibody
cocktail for treatment of Ebola infections is produced in glyco-
engineered XT/FT N. benthamiana (Castilho et al., 2011; Qiu
et al., 2014). In the XT/FT N. benthamiana the expression of
the β1,2-xylosyltransferase (XT) and core α1,3-fucosyltransferase
(FT) have been downregulated by an RNAi approach (Strasser
et al., 2008). In addition, mucin-type O-glycosylation has been
generated on N. benthamiana-produced mucin-derived peptides
and on recombinant erythropoietin fused to Fc (Castilho et al.,
2012; Yang et al., 2012).
Stable expression of a recombinant IgA (CaroRXTM) to
prevent dental caries has initially been performed in Nicotiana
tabacum plants (Ma et al., 1995). This pioneering work
demonstrated the potential of plants for the production of
functional recombinant sIgA. More recently, the production of
IgA variants in diﬀerent plant species has been reported, but there
are only few data available on the glycosylation of recombinant
plant-produced IgA variants (Karnoup et al., 2005; Paul et al.,
2014; Westerhof et al., 2014). Moreover, a comparison of N-
and O-glycans and attempts to modulate them in vivo have not
been described yet. In this study, we investigated the capability
of glyco-engineered wild-type and XT/FT N. benthamiana to
produce recombinant IgA1 with speciﬁc glycans. We transiently
expressed recombinant IgA1 against rotavirus (Juárez et al., 2012;
Juarez et al., 2013) and performed an analysis of the N-glycan
composition found in the CH2 domain as well as of the O-glycan
structures in the hinge region of the alpha chain. Our data provide
important insights for future strategies aiming at the production
of IgA1 variants with customized glycosylation and enhanced
therapeutic eﬀectiveness.
MATERIALS AND METHODS
Cloning and Expression Vectors
The human N-acetylglucosaminyltransferase II (GnTII)
coding sequence was ampliﬁed by PCR from human cDNA
(Mucha et al., 2002) with the primers Hs-GnTII1F (5′-
TATATCTAGAATGAGGTTCCGCATCTACAAACG-3′) and
Hs-GnTII2R (5′-tataGGATCCTCACTGCAGTCTTCTATAACT
TT-3′). The PCR product was digested with XbaI/BamHI and
ligated into XbaI/BamHI digested vector pPT2M (Strasser et al.,
2005) to generate pPT2M-GnTII. Binary expression vectors for
mucin-type O-glycan formation and CMP-sialic biosynthesis and
Golgi transport were available from previous studies (Castilho
et al., 2010, 2012). The multigene expression vector encoding
the alpha chain (αC), the lambda light chain (λC), the human
SC and the human joining chain (JC) was described in detail
recently (Juarez et al., 2013).
Plant Material and Transient Protein
Expression
Nicotiana benthamiana XT/FT plants which have strongly
reduced expression of β1,2-XT and core α1,3-FT (Strasser et al.,
2008) were grown in a growth chamber at 24◦C with a 16 h
light/8 h dark photoperiod. Five-week-old plants were used
for syringe-mediated agroinﬁltration into leaves as described
previously (Strasser et al., 2008). The recombinant sIgA1
was either expressed alone or co-inﬁltrated with the vectors
encoding the proteins for N-glycan modiﬁcation or mucin-type
O-glycosylation (OD600 of 0.2 for all agrobacteria containing
sIgA1 vectors and OD600 of 0.05 for all constructs involved in
glycan modiﬁcations).
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FIGURE 1 | Schematic overview of constructs for expression and
glyco-engineering. (A) A monomeric IgA1 with its different domains is
indicated. The N-glycosylation sites in the CH2 domain and in the tailpiece of
the alpha chain are marked using the symbols according to the nomenclature
from the Consortium for Functional Glycomics (http://www.
functionalglycomics.org/). The O-glycans in the hinge region are depicted by
yellow squares (GalNAc), yellow cycles (galactose) and purple diamonds (sialic
acid). (B) Illustration of the multigene expression vector for sIgA1. 35S,
cauliflower mosaic virus 35S promoter; SC, secretory component; t,
terminator sequence; JC, joining chain; αC, alpha chain; λC, lambda light
chain. (C) GnTII: human N-acetylglucosaminyltransferase II used for N-glycan
engineering. (D) Enzymes for sialylated core 1 formation: GalNAc-T2, human
polypeptide GalNAc-transferase 2; C1GalT1, Drosophila melanogaster core 1
β1,3-galactosyltransferase; ST6GalNAc, Mus musculus α2,6-sialyltransferase
III/IV; ST3Gal-I, human α2,3-sialyltransferase I.
Protein Extraction and Purification
To purify sIgA1, 40–50 g of leaf material was harvested four days
post inﬁltration, frozen in liquid nitrogen and disrupted using a
mixer mill. The homogenized leaf material was dissolved in 2 ml
extraction buﬀer (0.1 M Tris, 0.5 M NaCl, 1 mM EDTA, 40 mM
ascorbic acid, pH 6.8) per g of plant material and incubated
for 30 min at 4◦C. The extract was centrifuged at 27000 × g
for 30 min at 4◦C, passed through a ﬁlter with a pore size of
12–8 μm and centrifuged again. To clear the extract it was ran
through ﬁlters with pore sizes of 12–8 μm, 3–2 μm, 0.45 μm,
and 0.22 μm. A chromatography column was packed with 1 ml
of SSL7/Agarose (InvivoGen) and washed with 5 ml of PBS. The
cleared extract was applied to the column with a ﬂow rate of
∼1 ml/min. Afterwards the column was washed again with 5 ml
PBS and the protein was eluted with 5 ml of 0.1 M glycine pH 2.5.
The collected eluate fractions were immediately neutralized to pH
7.0 with 1 M Tris pH 8.0 and the protein content was analyzed
using the Micro BCA Protein Assay Kit (Thermo Scientiﬁc
Pierce) and bovine serum albumin (BSA) as a standard.
To isolate intercellular ﬂuid (IF) inﬁltrated leaves were
carefully detached and submerged in a beaker ﬁlled with buﬀer
(0.1 M Tris pH 7.5, 10 mMMgCl2, 2 mMEDTA). The beaker was
positioned in a desiccator and vacuumwas applied for 2 min. The
vacuum inﬁltrated leaves were inserted into a 50 ml falcon tube
with a ﬁne plain-weave cotton fabric (muslin bandage) inside to
prevent damage of the leaves and centrifuged at 1000 × g for
20 min at 4◦C. The IF was collected from the bottom of the tube
and directly used for further analysis or concentrated usingmicro
spin-columns.
Immunoblot Analysis and
Endoglycosidase Treatment
SDS-PAGE was performed in 8–10% polyacrylamide gels run
under reducing or non-reducing conditions. Separated proteins
were either detected by Coomassie Brilliant Blue staining or
by transfer onto nitrocellulose membranes (Hybond-C, GE
Healthcare) and subsequent detection with diﬀerent antibodies
and chemiluminescence-based detection reagents. Detection of
the αC was done using a polyclonal goat anti-human alpha chain
speciﬁc antibody (Sigma–Aldrich), the λC was detected using a
rabbit anti-human lambda light chain antibody (Sigma–Aldrich)
and the SC was detected using a rabbit anti-human SC antibody
(Gentaur).
Crude protein extracts, SSL7-pruﬁed sIgA1 or IF
fractions were subjected to enzymatic deglycosylation. For
endoglycosidase H (Endo H) digestion 1.5 μl of 10x Glycoprotein
Denaturing Buﬀer (NEB, 5% SDS, 0.4 M DTT) were added to
13.5 μl of sample. This mix was incubated for 10 min at 95◦C.
After the sample had cooled down on ice, 2 μl G5 Buﬀer (NEB),
1 μl Endo H (NEB) and 2 μl ultrapure water were added and
this mix was incubated for 60 min at 37◦C. For the peptide:
N-glycosidase F (PNGase F) digestion 1.5μl of denaturing buﬀer
were added to 13.5 μl of sample. This mix was incubated for
10 min at 95◦C. After the sample had cooled down on ice, 2 μl
G7 Buﬀer (NEB), 1 μl PNGase F (NEB), and 2 μl NP-40 were
added and this mix was incubated for 60 min at 37◦C.
N- and O-Glycan Analysis
To analyze the sIgA1N- andO-glycans, puriﬁed protein (1–5μg)
was separated by SDS-PAGE under reducing conditions, and
polypeptides were detected by Coomassie Brilliant Blue staining.
The corresponding band was excised from the gel, followed by
S-alkylation with iodoacetamide and digestion with sequencing
grade modiﬁed trypsin (Promega) or a combination of trypsin
and endoproteinase Glu-C (Roche). The peptide mixture was
analyzed using a Dionex Ultimate 3000 system directly linked to
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a QTOF instrument (maXis 4G ETD, Bruker) equipped with the
standard ESI source in the positive ion, DDA mode (=switching
to MS/MS mode for eluting peaks). MS-scans were recorded
(range: 150–2200 m/z, spectra rate: 1 Hz) and the six highest
peaks were selected for fragmentation. Instrument calibration
was performed using ESI calibration mixture (Agilent). For
separation of the peptides a Thermo BioBasic C18 separation
column (5 μm particle size, 150 × 0.360 mm) was used.
A gradient from 97% solvent A and 3% solvent B (Solvent A:
65 mM ammonium formiate buﬀer, B: 100% acetonitrile) to 32%
B in 45 min was applied, followed by a 15 min gradient from 32%
B to 75% B, at a ﬂow rate of 6 μL/min.
The analysis ﬁles were converted to XML ﬁles using Data
Analysis 4.0 (Bruker) and used to perform MS/MS ion searches
withMASCOT (embedded in ProteinScape 3.0, Bruker) using the
manually annotated and reviewed Swiss-Prot database. Peptide
MS/MS data were evaluated against the target sequence using X!
Tandem (www.thegpm.org/tandem/) with the following settings:
reversed sequences no; check parent ions for charges 1, 2, and 3
yes; models found with peptide log e lower -1 and proteins log e
lower -1; residuemodiﬁcations: oxidationM,W and deamidation
N, Q; isotope error was considered; fragment type was set to
monoisotopic; reﬁnement was used with standard parameters;
fragment mass error of 0.1 Da and ±7ppm parent mass error;
fragment types b and y ions; maximum parent ion charge of 4;
missed cleavage sites allowed was set to 2; semi-cleavage yes.
Jacalin Purification
Jacalin/Agarose (InvivoGen) was washed three times with PBS
and centrifuged at 1500 × g for 4 min. SSL7/Agarose-puriﬁed
IgA1 was diluted with PBS, added to the washed Jacalin/Agarose
and incubated for 1.5 h at 4◦C with slowly inverting. After
incubation, the mix was centrifuged at 3220 × g for 10 min,
the supernatant was removed and the Jacalin/Agarose was
transferred to a spin column. The agarose was washed three times
with 500 μl PBS and subsequent centrifugation at 1500 × g
for 1 min. The bound protein was eluted by the addition of
50 μl elution buﬀer containing 0.1 M α-D-galactose in PBS and
subjected to SDS-PAGE and immunoblotting.
RESULTS
Transient Expression of Recombinant
sIgA1 in N. benthamiana Wild-Type and
Glyco-Engineered XT/FT Plants
Recombinant sIgA1 against rotavirus was transiently expressed
via agro-inﬁltration in N. benthamiana wild-type and the
glyco-engineered XT/FT plants using the previously described
GoldenBraid multigene expression system (Juarez et al., 2013).
To obtain eﬃcient co-expression of all proteins the four
transcriptional units encoding the IgA1 alpha chain (αC), the
lambda light chain (λC), the human SC, and the human JC
were expressed from a single vector (Figure 1B). Extracts from
leaves were taken three days after inﬁltration and subjected
to SDS-PAGE and immunoblotting. Bands corresponding to
the expected size of the alpha chain (∼55 kDa), light chain
(∼23 kDa), and the SC (∼68 kDa) were found (Figure 2A).
By contrast, the JC could not be detected on immunoblots
(data not shown). The used anti-alpha chain antisera reacted
not only with the alpha chain, but also with the SC. SDS-PAGE
and immunoblotting under non-reducing conditions revealed
the presence of presumably monomeric IgA1 variants (signals
larger than 130 kDa and co-migrating with the lower bands
of the standard) in the total protein extract. Additional bands
at approximately ∼70 and 130 kDa were also detected with
the antibody against the SC and very likely represent free
monomeric and dimeric SC. Higher molecular weight complexes
resembling dimeric or sIgA1 (compare with the top bands
of the standard) were hardly detectable in all tested protein
fractions (Figure 2B). Importantly, these observations were
similar in wild-type as well as in glyco-engineered XT/FT
plants.
To further characterize the IgA variants, we puriﬁed them
from leaves using binding to SSL7-agarose and investigated
the presence of diﬀerent IgA chains in the IF. The SSL7-
puriﬁed protein consisted mainly of the alpha chain and the
light chain (Figure 2C), no additional band corresponding to
the J chain (∼17 kDa) was detected. The IF displayed the
SC as predominant sIgA1-derived protein band (Figure 2A).
In addition to the band corresponding to the SC, a faint
unidentiﬁed additional band (slightly larger than 100 kDa) was
also detected with anti-SC antibody. Interestingly, the alpha
chain was not found in the IF suggesting that the monomeric
IgA1 is not secreted to the apoplast. Together these ﬁndings
indicate that the expressed sIgA1 is not eﬃciently assembled
under the used conditions and that unassembled SC and
some unincorporated lambda light chain are secreted to the
apoplast.
Characterization of N-Glycosylation
Status of the Alpha Chain and Secretory
Component
Next, we examined the glycosylation status of the alpha chain
and the SC by endoglycosidase digestions and subsequent
SDS-PAGE and immunoblotting. Extracts from inﬁltrated wild-
type and XT/FT leaves were digested with Endo H and
PNGase F to distinguish between oligomannosidic (Endo H
and PNGase F sensitive), core fucose-free complex (Endo
H resistant, PNGase F sensitive), and core fucose-containing
N-glycans (insensitive to both enzymes).While EndoH digestion
of the alpha chain did not result in any mobility shift, a
small shift was observed in the PNGase F digested samples
(Figure 3A). The shift was comparable in wild-type and
XT/FT extracts indicating the presence of core fucose-free
complex N-glycans on the IgA1 alpha chain. This result was
conﬁrmed by digestion of the SSL7-puriﬁed protein samples
(Figure 3B). IF and leaf extracts were also analyzed for SC
N-glycosylation. In wild-type, a small mobility shift was visible
upon PNGase F digestion and immunoblotting in both the
IF and the extract. By contrast, in XT/FT the mobility shift
was much larger indicating that the majority of N-glycans
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FIGURE 2 | Analysis of sIgA1 expression. (A) SDS-PAGE and immunoblotting of crude protein extracts (Ex), SSL7-purified sIgA1 (P), and intercellular fluid (IF)
from N. benthamiana wild-type (wt) or XT/FT (XF) infiltrated plants with either anti-alpha chain (anti-αC), anti-secretory component (anti-SC), or anti-lambda light
chain (anti-λC) antibodies. (B) SDS-PAGE under non-reducing conditions followed by immunoblotting. (C) SDS-PAGE under reducing conditions and Coomassie
staining of SSL-purified sIgA1 from plants. Human serum IgA was loaded for comparison.
of the SC are core fucose-containing complex N-glycans
(Figure 3C).
To determine the N-glycan composition more in detail, IgA1
was puriﬁed via SSL7-agarose and subjected to SDS-PAGE and
Coomassie blue staining. The band corresponding to the alpha
chain was excised, trypsin digested and peptides were analysed
by LC-ESI-MS. The glycopeptide corresponding to the single
N-glycosylation site in the CH2 domain was identiﬁed and
found to harbor a single dominant peak (Figure 4A). The mass
of this peak corresponds to a glycopeptide with a complex
N-glycan furnished with a single terminal GlcNAc residue and
a single pentose, presumably β1,2-linked xylose. Other peaks
were reminiscent of a truncated glycan lacking terminal GlcNAc
(MMX:Man3XylGlcNAc2) and diﬀerent oligomannosidic (Man6
to Man9: Man6GlcNAc2 to Man9GlcNAc2) N-glycans. Fully
processed complex N-glycans were only found in very low
amounts (e.g., GnGnX: GlcNAc2Man3XylGlcNAc2; Figure 4A).
Consistent with the PNGase F digestion, no fucose-containing
peaks could be detected on the CH2 domain glycopeptide
in N. benthamiana wild-type. The N-glycan proﬁle from
the XT/FT-derived CH2 domain showed the incompletely
processed MGn (GlcNAcMan3GlcNAc2) structure as the major
peak and lower amounts of peaks corresponding to truncated
(MM:Man3GlcNAc2), complex (GnGn: GlcNAc2Man3GlcNAc2)
and oligomannosidic (Man6 to Man9) N-glycans. As expected,
glycans with β1,2-xylose and core α1,3-fucose were not found in
the glyco-engineered XT/FT line.
The presence of large amounts of N-glycan structures with a
single terminal GlcNAc residue in N. benthamiana suggests that
the N-glycan in the CH2 domain is incompletely processed by
the Golgi-resident GnTII or attached GlcNAc residues are cleaved
oﬀ in post-Golgi compartments by β-hexosaminidases (Strasser
et al., 2007; Castilho et al., 2014). To test the ﬁrst possibility,
human GnTII was cloned into a binary plant-expression vector
(Figure 1C) and co-expressed with the sIgA1 multigene vector.
As a result, peaks corresponding to complex N-glycans with two
terminal GlcNAc residues were considerably increased in wild-
type as well as in XT/FT (Figure 4B). This result indicates
that GnTII activity is a major limiting factor that leads to
incompletely processed N-glycans on this N-glycosylation site
of the IgA1 alpha chain. This limitation can at least in part be
overcome by transient expression of the corresponding human
glycosyltransferase.
In contrast to the plant-derived alpha chain N-glycans, the
CH2 domain glycopeptide from a human serum standard
displayed processing on both branches resulting in the
formation of sialylated and galactosylated biantennary
N-glycans (Figure 4C). The glycopeptide derived from the
alpha chain tailpiece could also be identiﬁed in the human IgA
standard. All identiﬁed peaks were sialylated and contained
fucose (Figure 4D). Despite several attempts using diﬀerent
proteolytic digestions (trypsin or Glu-C plus trypsin), a peptide
or glycopeptide containing the second N-glycosylation site in the
alpha chain tailpiece could not be identiﬁed in our plant-derived
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FIGURE 3 | Enzymatic deglycosylation of expressed sIgA1 chains.
(A) Crude protein extracts were digested with Endo H or PNGase F. Proteins
were separated by SDS-PAGE and analyzed by immunoblotting with
antibodies against the alpha chain (anti-αC). (B) SSL7-purified samples were
Endo H and PNGase F digested, respectively, subjected to SDS-PAGE
followed by immunoblotting with antibodies against the alpha chain. (C) IF and
crude extracts were digested with PNGase F and analyzed by SDS-PAGE and
immunoblotting with antibodies against the secretory component (anti-SC).
samples. Consequently, the N-glycosylation status of this site
remains unknown.
Since the SC could not be co-puriﬁed by SSL7-aﬃnity
puriﬁcation we isolated IF from leaves of wild-type plants,
extracted the corresponding band from SDS-PAGE and
analyzed the trypsin digested sample for glycopeptides.
In total four glycopeptides from the SC were identiﬁed,
one of them harboring two glycosylation sites. All
identiﬁed glycopeptides displayed a similar N-glycan
proﬁle (Figure 4E and data not shown) with a major peak
corresponding to GnGnXF (GlcNAc2Man3XylFucGlcNAc2)
and smaller amounts of incompletely processed (MGnXF:
GlcNAcMan3XylFucGlcNAc2) and truncated N-glycans
(MMXF: Man3XylFucGlcNAc2). All these N-glycans were
processed in the Golgi and contained xylose and fucose
residues.
O-Glycan Analysis of the IgA1 Hinge
Region
Plant O-glycosylation diﬀers signiﬁcantly from mammals as
plants do not have a functional mucin-type O-glycosylation
pathway (Castilho et al., 2012; Yang et al., 2012). Plants,
on the other hand, can convert proline residues adjacent to
O-glycosylation sites into hydroxyproline (Hyp; Taylor et al.,
2012). Serine residues next to speciﬁc Hyp-sequence motifs
may be modiﬁed with single galactose and Hyp residues
and can be extensively modiﬁed with arabinose chains or
arabinogalactans (Seifert and Roberts, 2007; Basu et al., 2013;
Saito et al., 2014). The presence of Hyp and arabinose
chains in the hinge region has been described previously for
maize seed-derived human IgA1 (Karnoup et al., 2005). To
monitor the prolyl-hydroxylation and potential plant-speciﬁc
O-glycosylation we analyzed the glycopeptide corresponding
to the hinge region from IgA1 expressed in N. benthamiana
wild-type and XT/FT plants. For this purpose, transiently
expressed IgA1 was puriﬁed from leaves using SSL7-agarose
and tryptic peptides were subjected to mass spectrometric
analysis. The peptide derived from the IgA1 alpha chain
(HYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPR) was
analyzed for the presence of post-translational modiﬁcations.
In Figure 5A, the spectra with peaks assigned to proline/Hyp
conversions are shown. The observed heterogeneity in the MS-
spectra indicates that proline residues in this region are partially
converted into Hyp by plant prolyl-hydroxylases. A search for
glycosylated variants of the peptide revealed the presence of
modiﬁcations corresponding to the incorporation of pentose
sugars (presumably arabinoses; Figure 5B). The modiﬁcations
were comparable between wild-type and XT/FT plants being
in agreement with the hypothesis that modulation of the
N-glycan processing pathway does not interfere with O-glycan
modiﬁcations.
Generation of Mucin-Type O-Glycans on
Plant-Expressed Human IgA1
Three to six mucin-type O-glycans are commonly attached to the
nine potential O-glycosylation sites in the hinge region of human
IgA1. The major structures are mucin-type core 1 and sialylated
core 1O-glycans. In IgA nephropathy, a long term chronic kidney
disease in humans, O-glycans are mostly galactose-deﬁcient
and recognized by anti-glycan antibodies leading to unwanted
immune complex formation. For therapeutic applications it is
therefore crucial to produce recombinant IgA variants with
human-type sialylated core 1 O-glycans to avoid any adverse
side eﬀects and loss of functionality (Suzuki et al., 2015). To
investigate whether the hinge region of human IgA1 can be
furnished with deﬁned mucin-type O-glycans when expressed
in N. benthamiana, we performed O-glycan engineering. To
this end, sIgA1 was co-expressed with diﬀerent enzymes for
initiation and elongation of mucin-type O-glycans (Figure 1D).
For initiation of mucin-type O-glycosylation we chose to express
human GalNAc-T2 which we have previously used for in
planta O-glycan biosynthesis on the single O-glycosylation
site of EPO-Fc (Castilho et al., 2012). As can be seen in
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FIGURE 4 | N-glycan analysis of sIgA1. (A) Mass spectra of the tryptic
glycopeptide from the CH2 domain of sIgA1 expressed in N. benthamiana
wild-type (wt) or XT/FT (XF). The amino acid sequence of the identified
peptide is highlighted. The N-glycosylation site is underlined. (B) sIgA1 was
transiently co-expressed with human GnTII and analyzed as mentioned in (A).
(C) The corresponding Glu-C/trypsin digested glycopeptide from human
serum IgA. (D) The spectrum of the tailpiece glycopeptide of the alpha chain
from human serum IgA. (E) Spectra from two glycopeptides of the SC derived
from the IF of wild-type plants. A detailed explanation of the used N-glycan
abbreviations can be found at the ProGlycAn homepage
(http://www.proglycan.com/index.php?page=pga_nomenclature). The
graphical depictions of glycan-structures follow the style of the Consortium for
Functional Glycomics (http://www.functionalglycomics.org/static/consortium/
Nomenclature.shtml).
Figure 6A, co-expression of sIgA1 with this single human
enzyme (without any additional mammalian proteins like a
UDP-GalNAc transporter) resulted in modiﬁcation of the hinge
FIGURE 5 | MS analysis showing the presence of plant specific
O-glycan modifications. The analyzed peptide sequence with potential
O-glycosylation sites (highlighted in bold) is shown. (A) The glycopeptide
corresponding to the alpha chain hinge region contains different amounts of
hydroxyproline (Hyp) residues. (B) Peaks corresponding to Hyp + pentoses
(Pent) were detected in wild-type and XT/FT plants.
region peptide with an additional HexNAc monosaccharide
(Tn antigen-like structure). Co-expression of the Drosophila
melanogaster β1,3-galactosyltransferase (C1GalT1) led to the
incorporation of additional hexoses suggesting the successful
formation of core 1 O-glycan structures (T antigen; Figure 6B).
The T antigen structure is recognized by the lectin jacalin
which is commonly used for puriﬁcation of human IgA1.
Previously it was demonstrated that recombinant jacalin does
not react with plant-produced sIgA1 which is normally devoid
of any galactose or GalNAc residues (Fernandez-del-Carmen
et al., 2013). Here, we tested whether a commercially available
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jacalin recognizes glyco-engineered sIgA1 puriﬁed from plants.
Jacalin-agarose was incubated with diﬀerent sIgA1 glycoforms
and binding was tested by immunoblotting. Jacalin binding was
observed for sIgA1 modiﬁed with GalNAc-T2 and for sIgA1
modiﬁed with GalNAc-T2 and C1GalT1. By contrast, no binding
was observed for unmodiﬁed sIgA1 or for sIgA1 that was co-
expressed with human β1,4-galactosyltransferase (Strasser et al.,
2009) that acts predominately on N-glycans (Figure 6C).
Finally, to generate disialylated core 1 structures, the
predominant O-glycan on serum-derived IgA1, we co-expressed
sIgA1 with GalNAc-T2, C1GalT1, and the mammalian sialic
acid biosynthesis pathway consisting of three enzymes (UDP-N-
acetylglucosamine 2-epimerase/N-acetylmannosamine kinase;
N-acetylneuraminic acid phosphate synthase and CMP-N-
acetylneuraminic acid synthetase) for CMP-sialic acid formation
and the CMP-sialic acid transporter for transport of the activated
nucleotide sugar into the Golgi (Castilho et al., 2012). The MS-
spectra showed distinct peaks corresponding to the generation of
structures with HexNAc, hexoses, and N-acetylneuraminic acid
(NeuAc; Figure 7A), which are similar to the structures found on
human serum IgA1 (Figure 7B). In summary, these data show
that diﬀerent mucin-type O-glycans can be successfully generated
on the hinge region of N. benthamiana-expressed sIgA1.
DISCUSSION
Glycosylation of the single IgG Fc-N-glycan has a huge impact
on Fc-receptor binding leading to alterations in eﬀector functions
such as antibody dependent cellular cytotoxicity (ADCC). While
the relevance of antibody glycosylation for eﬀector functions
has been realized some time ago (Lifely et al., 1995; Umaña
et al., 1999), more recent in vivo and in vitro glyco-engineering
approaches have resulted in a much deeper understanding of
antibody glycan-structure-function relationships (Forthal et al.,
2010; Ferrara et al., 2011; Ahmed et al., 2014; Lin et al., 2015;
Subedi and Barb, 2015). As a consequence the Fc glycans are
now categorized as critical quality attributes by industry (Reusch
and Tejada, 2015). Despite this documented importance for
IgG the role of glycosylation for other immunoglobulins is less
well understood. Crucial for further developments and novel
applications are suitable tools to manipulate and control the
glycan composition on diﬀerent immunoglobulins including
IgMs and IgAs. Glyco-engineering has been very successfully
applied to plants in the past (Strasser et al., 2014) and the
great potential of N. benthamiana for production of therapeutic
IgMs has recently been demonstrated (Loos et al., 2014). Here,
we characterized N- and O-glycans from sIgA1 produced in
wild-type and glyco-engineered XT/FT plants and provided
strategies toward the formation of deﬁnedN- as well asO-glycans
that can be used in the future for extensive functional studies.
We initially aimed to produce a sIgA1 variant and co-
expressed all four involved protein chains from a single
expression construct (Juarez et al., 2013). Unexpectedly, we
obtained mainly monomeric IgA1 variants indicating that the
assembly to full sIgA1 variants was not eﬃcient. One possible
factor that inﬂuences the formation of dimeric and sIgA variants
FIGURE 6 | Co-expression of GalNAc-T2 and C1GalT1 results in the
modification of the hinge region peptide. (A) Co-expression of
GalNAc-T2 leads to the incorporation of HexNAc residues. (B) Co-expression
of GalNAc-T2 and C1GalT1 results in the generation of core 1 structures:
HexNAc + hexose (Hex). (C) Incubation with jacalin agarose (+) reveals
binding of the sIgA1 alpha chain when modified in planta with mucin-type
O-glycan biosynthesis enzymes. The amount of sIgA1 before binding to jacalin
is also shown (−). Human serum IgA was used as a positive control and sIgA1
alone or co-expressed with the N-glycan modifying β1,4-galactosyltransferase
(GalT) was used as negative control.
could be the limited expression of the J chain. In our immunoblot
experiments, we were not able to monitor the expression of the J
chain. Even the additional co-expression of the human J-chain
did not result in a detectable J chain incorporation (data not
shown). Alternatively, the fate of the alpha chain tailpiece could
also aﬀect the assembly of the dimeric or secretory form. We
obtained good coverage of the human IgA1 alpha chain in the
proteolytically digested peptide pools (data not shown), but were
not able to detect the glycosylated or unglycosylated peptide
corresponding to the C-terminal tailpiece. While we might have
missed the (glyco)peptide during analysis it is also possible
that the C-terminal end of the alpha chain is cleaved oﬀ in
plants. Another recent study has detected diﬀerence in IgA alpha
chain mobility by immunoblotting which was proposed to result
from partial N-glycosylation of the tailpiece when transiently
expressed inN. benthamiana (Westerhof et al., 2014). As previous
studies in mammals have indicated an important role of the
N-glycan in the tailpiece for J chain incorporation (Atkin et al.,
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1996; Sørensen et al., 2000), an eﬀect of the altered C-terminal
end on sIgA1 formation is plausible. Future studies will aim to
address the nature of N-glycosylation in the tailpiece and its
contribution for dimeric and sIgA1 formation in plants.
Analysis of the IF revealed that only the SC and light chain
are present in considerable amounts, while most of the alpha
chain and assembled IgA1 remains in the cells. A similar scenario
of ineﬃcient secretion of assembled IgA variants has been
described for three IgA1 variants when transiently expressed in
N. benthamiana wild-type (Westerhof et al., 2014). While the
ﬁnal subcellular location of the described IgA1 antibodies was
not determined, another study reported the accumulation of sIgA
mainly in the vacuoles of N. benthamiana leaves (Paul et al.,
2014). However, in contrast to our ﬁndings, the sIgA in the
later study showed predominately oligomannosidic N-glycans
indicating a diﬀerent subcellular traﬃcking route that bypasses
the Golgi apparatus. We detected high amounts of truncated or
incompletely processed complex N-glycans lacking core fucose
on the N-glycosylation site in the CH2 domain of the alpha
chain. In wild-type N. benthamiana, recombinant glycoproteins
such as IgGs (Strasser et al., 2009), EPO-Fc (Castilho et al.,
2012), α1-antitrypsin (Castilho et al., 2014), or IgM (Loos et al.,
2014) that travel through the Golgi are very eﬃciently processed
and frequently modiﬁed with both β1,2-xylose and core α1,3-
fucose residues. Although not directly shown by site-speciﬁc
glycopeptide analysis, the lack of core α1,3-fucosylation on
IgA1 has also been observed based on PNGase F digestions
and immunoblots by Westerhof et al. (2014). This uncommon
lack of core α1,3-fucosylation is very likely caused by protein
intrinsic features and less dependent on the expression host as the
same glycopeptide from human serum IgA (Figure 4C) displays
also reduced levels of core fucose. Moreover, recombinant IgA1
produced in murine myeloma or Chinese hamster ovary cells
harbors also considerable amounts of complex N-glycans devoid
of core fucose (Yoo et al., 2010). Interestingly, a supportive role of
core α1,3-fucosylation on IgG Fc-glycan processing was recently
discovered by analysis of the plant-produced cetuximab IgG1
antibody (Castilho et al., 2015).
Another diﬀerence to recombinant IgG expressed in
N. benthamiana is the presence of incompletely processed or
truncated complex N-glycans. These structures may derive
either from ineﬃcient GnTII activity during N-glycan
processing in the Golgi or from post-Golgi action of plant
β-hexosaminidases (Strasser et al., 2007). Co-expression
of human GnTII converted a signiﬁcant portion of the
oligosaccharide into fully processed complex N-glycans
indicating a limitation in endogenous GnTII activity. Whether
β-hexosaminidases play an additional role in generation of
N-glycan microheterogeneity like it has been shown for α1-
antitrypsin (Castilho et al., 2014) remains to be shown in the
future.
O-Glycan Engineering: Challenges and
Future Goals
The analysis of the IgA1 hinge region from wild-type or
XT/FT plants revealed the presence of plant-type Hyp
FIGURE 7 | In planta generation of sialylated core 1 structures on the
alpha chain hinge region. (A) Mass-spectrum of trypsin-digested sIgA1
expressed in N. benthamiana XT/FT (XT) line is shown. sIgA1 was
coexpressed with GalNAc-T2, C1GalT1, ST6GalNAc-III/IV, ST3Gal-I and the
required proteins for CMP-sialic acid synthesis and Golgi-transport to
generate disialyl core 1 structures. The inset shows peaks corresponding to
modifications of four O-glycosylation sites with sialic acid (4–4–8: 4x hexose –
4x HexNAc – 8x N-acetylneuraminic acid). (B) For comparison, the O-glycan
structures derived from human serum IgA are indicated.
formation and minor amounts of additional sugar residues.
These posttranslational modiﬁcations have also been previously
described for recombinant IgA1 expressed in maize seeds
(Karnoup et al., 2005), on EPO-Fc (Castilho et al., 2012),
on mucin-type glycopeptides expressed in N. benthamiana
(Pinkhasov et al., 2011; Yang et al., 2012) and on moss-produced
EPO (Parsons et al., 2013). All of these proteins have exposed
proline residues next to O-glycosylation sites. The presence
of these non-human modiﬁcations on therapeutic IgA1s may
signiﬁcantly aﬀect the product quality and cause unwanted
immune reactions. Therefore strategies are needed to avoid Hyp
formation. Themost promising approach is the elimination of the
responsible prolyl-4-hydroxylase activity. Targeted disruption of
a speciﬁc prolyl-4-hydroxylase in moss resulted in the removal
of prolyl-hydroxylation on moss-produced recombinant EPO
(Parsons et al., 2013). Given the success of the xylosyl- and
fucosyltransferase knockdown in XT/FT (Strasser et al., 2008)
a similar strategy should also be feasible for elimination of
unwanted plant-speciﬁc modiﬁcations related to O-glycans.
Compared to N-glycans, engineering of mucin-type
O-glycosylation is highly challenging as a mammalian-like
mucin-type O-glycan biosynthesis pathway is absent from
plants (Strasser, 2013). The de novo synthesis of deﬁnedO-glycan
structures in plants requires the coordinated expression of several
diﬀerent mammalian proteins in the secretory pathway of plants.
However, the knowledge of factors that control mucin-type
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O-glycan biosynthesis in mammals is incomplete (Bennett et al.,
2012). The initiation of mucin-type O-glycosylation, for example,
is carried out by the large family of mammalian polypeptide
GalNAc-transferases with 20 members in humans. Eﬃcient
transfer of GalNAc to multiple sites often requires the activity of
diﬀerent polypeptide GalNAc-transferase isoforms. Despite some
recent progress, the acceptor substrate speciﬁcity of individual
members from this family is still largely unclear (Steentoft et al.,
2013; Kong et al., 2015). Here, we used the human GalNAc-
T2, which is the key enzyme for IgA1 O-glycosylation initiation
(Iwasaki et al., 2003). Our ﬁndings indicate that GalNAc can
be eﬃciently transferred to Ser/Thr residues present in the
IgA1 alpha chain hinge region when co-expressed with human
GalNAc-T2 in plants. While further elongation with galactose
and sialic acid led to human IgA1-like O-glycan structures, the
incorporation of sialic acid was not very eﬃcient. In the future,
the biosynthesis of disialylated core 1 O-glycans can be further
optimized by the use of multigene vectors for expression of all
glycosyltransferases, by more precise subcellular targeting of the
mammalian enzymes (Strasser et al., 2014) as well as by the use
of transgenic N. benthamiana lines that stably express parts of
the pathway (e.g., all the genes for CMP-sialic acid synthesis;
Castilho et al., 2008). Together these advances will pave the
way for detailed functional analysis of individual IgA glycoforms
with the ultimate aim to generate recombinant glycoprotein
therapeutics in N. benthamiana with reduced adverse side eﬀects
and maximized eﬃcacy.
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